Active substances: Clomiphene
All men reported improvements in the post-treatment QoL scores. No serious adverse events were recorded.
FSH is important in the first stage of sperm production, or spermatogenesis. Increasing the level of these hormones in the body can lead to an increase in testosterone and the creation of more sperm.
However, hormone interactions are complex, and there is not currently enough research to know whether boosting LH and FSH has a direct impact on male fertility. According to one review, there have been mixed results from clinical studies testing the effectiveness of taking clomiphene citrate for male infertility.
Motility refers to how well sperm move through the female reproductive system to fertilize an egg.
Two to three days after Provera is completed, a menstrual period should begin. On the 3 rd, 4 th or 5 th day of menstrual flow, a course of clomiphene is started.
A clomiphene citrate 50 mg tablet is taken orally for 5 days. On day 11 or 12 of the menstrual cycle, ultrasound monitoring is conducted to determine if an ovarian follicle or follicles have developed.
Also at this time, patients are asked to use an ovulation predictor kit to test their urine for a surge in LH luteinizing hormone indicating that eggs have matured and ovulation is imminent.
Natural intercourse or insemination is timed to ovulation.
If ovulation has been assisted by an hCG injection, a form of the hormone progesterone is given via vaginal tablets or gel. The progesterone hormone serves to support the endometrial uterine lining and prepare it for the fertilized egg.
If the test is positive, a blood test will be performed to confirm results. If ovulation doesn't occur during this initial clomiphene dosage, another course of provera will be prescribed and the dose of clomiphene increased until ovulation occurs.
This is sometimes referred to as "superovulation. Starting clomiphene early in the cycle helps with the recruitment of more than one mature egg. This was contrasted to that seen after 6 weeks of continuous daily oral or transdermal treatment day 42.
The pharmacokinetics of enclomiphene citrate were assessed in a select subpopulation.
Serum samples were obtained over the course of the study to determine the levels of various hormones and lipids.
All three doses of enclomiphene citrate increased the testosterone concentration at time 0 of each 24-h sampling period, and the mean, maximum, minimum and range of testosterone concentrations over the 24-h sampling period.
Transdermal testosterone also raised total testosterone, albeit with more variability, and with suppressed LH levels. The patterns of total testosterone over the 24-h period after 6 weeks of dosing could be fit to a nonlinear function with morning elevations, mid-day troughs, and rising night-time levels.